HENDERSON MICHAEL THOMAS 4
4 · Apogee Therapeutics, Inc. · Filed Nov 13, 2025
Insider Transaction Report
Form 4
HENDERSON MICHAEL THOMAS
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-11-13$64.52/sh−100$6,452→ 1,272,987 total - Sale
Common Stock
2025-11-13$61.93/sh−3,340$206,846→ 1,289,647 total - Sale
Common Stock
2025-11-13$63.89/sh−1,786$114,108→ 1,273,087 total - Sale
Common Stock
2025-11-13$63.14/sh−14,774$932,830→ 1,274,873 total
Footnotes (4)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.45 to $62.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.50 to $63.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.52 to $64.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.